Clinuvel Pharmaceuticals Ltd (CUVL) › R&D ExpenseClinuvel Pharmaceuticals Ltd (CUVL): R&D ExpenseAnnual figures by period end, from SEC filings.$12.23MYear ended 2026-06-30$13.22M2024-06-30: $9.99M2025-06-30: $13.22M2026-06-30: $12.23M$12.23M2024-06-30 R&D Expense (USD) 2026-06-30Period endedR&D ExpenseChange YoYSource filing2026-06-30$12.23M-7.5%2026-10-30, From 2025-07-012025-06-30$13.22M+32.2%2026-10-30, From 2024-07-012024-06-30$9.99Mn/a2026-10-30, From 2023-07-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresFree Cash FlowShare RepurchasesDividends PaidShares OutstandingWeighted Average Diluted SharesEPS (Basic)